HARWELL, Oxford, UK — September 17, 2026
MitoRx Therapeutics announced that new data for its lead mitochondrial-targeted small molecule MTRX31 will be presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from September 28 to October 2, 2026. The oral presentation will provide new insights into the compound’s differentiated mechanism of action and its effects on body weight in a diet-induced obesity (DIO) mouse model. According to MitoRx, the data further characterize how MTRX31 restores the balance between fat and carbohydrate oxidation, targeting a metabolic mechanism that becomes impaired in obesity. The presentation is scheduled for September 30 and will be delivered by Xavier Jacq, Chief Scientific Officer of MitoRx Therapeutics..
MTRX31 Targets Metabolic Flexibility Through Mitochondria
MTRX31 is designed to restore healthy mitochondrial metabolism rather than primarily suppress appetite, representing a differentiated approach to obesity drug development. MitoRx is developing the compound for people with high-risk obesity, a form of metabolically unhealthy obesity associated with visceral adiposity, insulin resistance, lipotoxicity and mitochondrial dysfunction. The company’s development strategy centers on restoring metabolic flexibility, particularly the ability to appropriately switch between fat and carbohydrate oxidation. New structural biology and other preclinical findings to be presented at EASD are expected to provide additional characterization of MTRX31’s molecular target and mode of action. MitoRx said the data point to a single, unique and well-characterized molecular target, supporting the company’s positioning of MTRX31 as a potential first-in-class mitochondrial approach.
Preclinical Study Evaluates Weight Loss and Body Composition
The EASD presentation will include new data from diet-induced obesity mice studied under thermoneutral conditions, an established preclinical model used to evaluate metabolic therapies. The presentation is titled “MTRX31 induces bodyweight loss in diet-induced obesity mice at thermoneutrality by switching metabolism from fat to carbohydrate oxidation.” Previous company-reported research found that MTRX31 reduced body weight and fat mass while preserving lean mass and improving metabolic parameters. MitoRx also reported greater and more durable weight loss than tirzepatide at the doses evaluated in its preclinical studies. The company’s development hypothesis is that restoring mitochondrial metabolic function could produce durable, quality weight loss with preferential fat reduction and preservation of lean tissue, while potentially improving broader measures of metabolic health. These findings remain preclinical and will require validation through clinical development.
Advertisement
MitoRx Builds MTRX31 Toward Clinical Development
The EASD presentation represents an opportunity for MitoRx to further define the scientific foundation of MTRX31 and its potential role in obesity treatment. The company is focused on high-risk obesity, which it estimates affects approximately 25–40% of people with obesity and is associated with increased risk of metabolic-associated fatty liver disease, metabolic-associated steatohepatitis, type 2 diabetes and atherosclerotic cardiovascular disease. By targeting mitochondrial metabolism rather than appetite suppression, MitoRx is pursuing a distinct therapeutic strategy that could address both weight and metabolic dysfunction. The company’s continued characterization of MTRX31’s molecular target, mechanism and preclinical efficacy will be important as the program progresses toward potential clinical development. The upcoming EASD data are expected to strengthen the company’s mechanistic and translational case for MTRX31 as a potential mitochondrial-targeted obesity therapy.
Source: MitoRx Therapeutics, press release
